| Your Space |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Diabetes > Pancreas Transplants - A Solution For Type 1 Diabetes Sufferers? |
|
Your Space - Pancreas Transplants - A Solution For Type 1 Diabetes Sufferers?
Type 1 diabetes was formerly known as juvenile diabetes or insulin dependent diabete According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product s mellitus. Type 1 diabetes matures quickly and symptoms are very visible. This typ ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in of diabetes occurs when the body’s immune system destroys pancreatic cells. These c lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ells are the insulin producing cells. This type of diabetes affects mostly children here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe nd young adults. Risk factors for type1 diabetes include autoimmune, genetics, and e d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nvironmental factors. Many clinical studies have shown that an option for type 1 di ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc betes treatment is the pancreas transplantation. For some patients, surgeons can res easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi tore the function of the pancreas with an islet cell transplant. The most important nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically benefit of pancreas transplantation is freedom from dependence on insulin. Although and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ this is significant, this is not recommended treatment for diabetes unless there is ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi need for a kidney transplant as well. On the other hand, pancreas transplants stil ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a l remains problematic in that the immune system still can attack new pancreas cells. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod Some people who have transplants do find that the transplanted pancreas is attacked cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin and the insulin-producing cells are killed off after operation. At this time, pancr tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen as transplants do not always provide permanent cures, and people who have transplant t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel s must take anti-rejection medication and immune-system suppressing drugs. Many res ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust arch teams are still working on this immune system problem that seems to be the roo y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products t cause of type 1 diabetes (sometimes called auto-immune diabetes). This is main re . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de son that pancreas transplants are still only being studied experimentally and are no elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip t considered currently to be an automatic cure for all patients with type 1 diabetes tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Find Out The Truth About Taking Herbs For Anxiety Cinnamon Promotes Healthy Glucose Levels
|